A series of novel 2-substituted methlthio-5-(4-amino-2-methylpyrimidin-5-yl-)-1,3,4-thiadiazole derivatives were synthesized, characterized and evaluated for antiviral activities against tobacco mosaic virus (TMV). The preliminary biological results indicated that most compounds exhibit excellent antiviral activity against TMV in vivo. Among these compounds, compounds 9c, 9i, and 9p displayed the similar curative effect against TMV (EC 50 = 287.05-322.47 μg/mL) to that of the commercial agent Ningnanmycin (EC 50 = 301.83 μg/mL). In particular, compound 9d demonstrated the best curative effect against TMV (EC 50 = 266.21 μg/mL), which was better than that of commercial Ningnanmycin.